Cesar Alaniz is is a Clinical Associate Professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy and a clinical pharmacist for the adult medical intensive care unit in the University of Michigan Hospitals and Health Centers (UMHHC). He serves on a variety of committees within UMHHC and the College of Pharmacy. His principal area of research is in critical care phamacotherapy.

Selected Publications

  • Mohammad RA, Regal R, Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother. 2012; 46:1559-63.

  • Alaniz C, Pogue JM. Vancomycin versus linezolid in the treatment of methicillin-resistant staphylococcus aureus pneumonia: implications of the zephyr trial. Ann Pharmacother. 2012;46:1432-45.

  • Miller JT, Welage LS, Kraft MD, Alaniz C. Does body weight impact the efficacy of vasopressin in the management of septic shock? J Crit Care. 2012;27:289-93.

  • Pettit RS, Zimmerman CR, Alaniz C, Dorsch MP. Cost analysis before and after implementation of a computerized physician order entry form for enoxaparin. P T. 2012;37:107-11.

  • Alaniz C, Hyzy RC. Albumin meta-analysis and epochs of care. Crit Care Med. 2011;39:1852.